Sandoz H1 FY26 core diluted EPS rises 17% to USD 1.71; net sales climb 15% to USD 5.8 billion

PUBT · 2d ago
Sandoz H1 FY26 core diluted EPS rises 17% to USD 1.71; net sales climb 15% to USD 5.8 billion
  • Sandoz posted H1 2026 net sales of USD 5.8 billion, up 15%.
  • Core-EBITDA margin widened 90 bps to 20.9%, while core diluted EPS climbed 17% to USD 1.71.
  • Management free cash flow was unchanged at USD 503 million.
  • Expanded the biosimilars pipeline to 36 assets; expected H2 2026 biosimilar launches include Enzeevu (aflibercept) and Ranluspec (ranibizumab).
  • Confirmed full-year 2026 guidance for mid-to high-single-digit net-sales growth and a core-EBITDA margin increase of about 100 bps.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.